ArticleBMC nephrology2025
Effectiveness and safety of telitacicept in IgA nephropathy: a propensity score matching analysis with a 6-month follow-up.
Article in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Telitacicept for IgA nephropathy: a systematic review and meta-analysis of observational studies.Frontiers in medicine · 2026Pooled it
- Immune-mediated renal injury and cardiometabolic risk in IgA nephropathy: clinical evidence on telitacicept from a scoping review.Frontiers in nutrition · 2026Pooled it
- Review
- Efficacy and safety of Telitacicept in IgA nephropathy and its impact on urinary Gd-IgA1: insights from a real-world study.Frontiers in immunology · 2026Article
- Telitacicept in IgA Nephropathy Patients with Severe Renal Impairment: A Case Series.Kidney diseases (Basel, Switzerland)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate efficacy and safety of telitacicept in IgA nephropathy (IgAN) in a real-world setting.
methodsThis study is a retrospective, single-center study that included 33 IgAN patients from Xin Hua Hospital affiliated to Shanghai Jiao Tong University School of Medicine. Eleven patients received telitacicept treatment for at least 3 months. A control group was matched using propensity score matching. Clinical assessments and laboratory tests were performed at baseline and subsequently every one to three months during the treatment period. Clinical outcomes were assessed at 3 and 6 months.
resultsAt 3 months, 24-hour urinary protein in the telitacicept group decreased by 893.29 mg/day (63.90%). The telitacicept group achieved a complete remission rate of 36.36% and a partial remission rate of 36.36%. Similarly, the control group exhibited a complete remission rate of 31.82% and a partial remission rate of 36.36%. At 6 months, although the telitacicept group showed lower 24-hour urinary protein than the control group, the difference was not statistically significant [381.68 (182.52–990.00) mg/day vs. 480.15 (185.28–905.15) mg/day, P = 0.567]. Complete remission rates for the telitacicept and control groups increased to 54.55% and 36.36%, with overall remission rates of 72.73% and 77.27%, respectively. Serum creatinine and eGFR remained stable throughout the study. The most common adverse reactions were pain, redness, or itching at injection site, without signs of local infection.
conclusionPreliminary clinical trials have provided supportive evidence for the efficacy and safety of telitacicept as a viable treatment option for IgAN. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.